A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

NCT04385550 PHASE3 UNKNOWN

This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or standard second-line chemotherapy, with 1:1 random ratio.

Details

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	PHASE3
Status	UNKNOWN
Enrolment	528
Start date	Wed May 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Dec 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Interventions

• Anlotinib hydrochloride capsule
• AK105 injection
• Paclitaxel injection
• Docetaxel injection

Countries

China